Which hedge funds own PCVX? VAXCYTE INC, Q2 2026 13F holders
Healthcare · Open on the interactive board
9 of the hedge funds tracked by WhaleCreep disclosed a position in PCVX (VAXCYTE INC) in their Q2 2026 13F filings, worth $914.4m in total. The largest holder by portfolio weight is RA Capital Management at 5.8% of its book. 3 exited: Baupost Group, Farallon Capital Management, Point72 Asset Management LP.
9tracked managers holding
0opened this quarter
3exited this quarter
Which hedge funds hold PCVX? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| RA Capital Management | Q2 2026 | 5.8% | $667.0m | 11,474,599 | 0% | held |
| Maverick Capital | Q2 2026 | 0.8% | $93.8m | 1,613,242 | 17% | added |
| D. E. Shaw & Co | Q2 2026 | 0.1% | $110.6m | 1,901,872 | -34% | reduced |
| Woodline Partners | Q2 2026 | 0.0% | $16.0m | 274,740 | 0% | held |
| WCM Investment Management | Q2 2026 | 0.0% | $14.1m | 243,502 | 116% | added |
| Brevan Howard Capital Management | Q2 2026 | 0.0% | $984.4k | 16,935 | 45% | added |
| Bridgewater Associates | Q2 2026 | 0.0% | $2.9m | 50,217 | 289% | added |
| Millennium Management | Q2 2026 | 0.0% | $7.9m | 136,625 | -53% | reduced |
| Renaissance Technologies LLC | Q2 2026 | 0.0% | $1.1m | 19,634 | -64% | reduced |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Baupost Group | 15.2% | $46.5m |
| Farallon Capital Management | 3.0% | $73.3m |
| Point72 Asset Management LP | 0.8% | $36.1m |
How has hedge fund ownership of PCVX changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 9 | $914.4m |
| Q1 2026 | 12 | $1.1bn |
| Q4 2025 | 6 | $580.7m |
| Q3 2025 | 7 | $517.4m |
| Q2 2025 | 6 | $450.9m |
| Q1 2025 | 7 | $570.4m |
| Q4 2024 | 7 | $939.4m |
| Q3 2024 | 7 | $1.3bn |
| Q2 2024 | 6 | $775.4m |
| Q1 2024 | 5 | $656.7m |
| Q4 2023 | 5 | $558.2m |
| Q3 2023 | 4 | $493.4m |
| Q2 2023 | 6 | $479.5m |
| Q1 2023 | 6 | $337.7m |
| Q4 2022 | 7 | $418.8m |
| Q3 2022 | 6 | $145.6m |
Counts every tracked manager that disclosed PCVX in that quarter's filing, including managers that have since stopped filing.